Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

Several Ohio medical spas including two in the Mahoning Valley were sent letters by the Ohio Attorney General's Office ...

A Kentucky doctor faces up to three years in prison after admitting he sold patients a non-approved weight-loss drug. Matthew ...

The Ohio attorney general's office issues warning letters to more than a dozen medical spas across the state for misleading claims about compounded versions of Ozempic, Wegovy and Mounjaro.

HealthDay News — The rate of emergency department visits for adverse events among patients dispensed semaglutide is low, with most visits involving gastrointestinal effects, according to a research ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

The FDA and the manufacturer of Ozempic, Novo Nordisk are urging patients, doctors and pharmacies to check their Ozempic ...

A Kentucky physician is facing up to three years in prison after distributing non-FDA approved semaglutide drugs, prosecutors ...

Semaglutide is an injectable medication that treats type 2 diabetes and obesity by regulating blood sugar levels. A ...

With Semaglutide, postmenopausal women can achieve significant weight loss, improve insulin sensitivity, and lower the risk ...

After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering ...

Presentation Title: Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass and Physical Function in Older Patients Receiving Semaglutide for Weight Loss Date: April 30, 2025 Start time: 12:30 ...